Latvia Pharmaceuticals & Healthcare Q1 2019
Years of underfunding has severely restricted patient access to healthcare services in Latvia and dampenedpharmaceutical sales. The introduction of health insurance will result in a significant boost to public healthcare finances and areduction in out-of-pocket payments. Multinational pharmaceutical firms will thus benefit from increased funding for medicinereimbursement. However, Latvia will remain an insignificant market for drugmakers relative to its EU peers on account of its smallpopulation size.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook